In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes
- PMID: 2175768
- DOI: 10.1007/BF02427832
In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes
Abstract
Glioblastoma cells constitutively produce various amounts of PGE2 (prostaglandin E2) in vitro. The amounts of PGE2 found in the conditioned medium of the glioblastoma cultures (less than 5 ng/ml) were not enough to inhibit the IL-2 (interleukin-2) activation of peripheral blood lymphocytes. However the amount of PGE2 produced by approximately 1 x 10(7) of the glioblastoma cells can be assumed to suppress the generation of IL-2-induced killing activity against glioblastoma cells.
Similar articles
-
Influence of PGE2- and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes.J Neurosurg. 1990 Apr;72(4):619-25. doi: 10.3171/jns.1990.72.4.0619. J Neurosurg. 1990. PMID: 1969467
-
The augmentation of lymphokine-activated killer cell activity by indomethacin in vitro is not mediated by prostaglandin E2 suppression.Proc Natl Sci Counc Repub China B. 1993 Oct;17(4):138-42. Proc Natl Sci Counc Repub China B. 1993. PMID: 8171164
-
Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.Cancer. 1993 Jul 15;72(2):491-501. doi: 10.1002/1097-0142(19930715)72:2<491::aid-cncr2820720227>3.0.co;2-1. Cancer. 1993. PMID: 8319179
-
Prostaglandin E2 from macrophages of murine splenocyte cultures inhibits the generation of lymphokine-activated killer cell activity.Tumour Biol. 1991;12(2):99-110. doi: 10.1159/000217694. Tumour Biol. 1991. PMID: 2028183
-
Enhancement of in vitro prostaglandin E2 production by mouse fibrosarcoma cells after co-culture with various anti-tumour effector cells.Br J Cancer. 1994 Aug;70(2):233-8. doi: 10.1038/bjc.1994.285. Br J Cancer. 1994. PMID: 8054271 Free PMC article.
Cited by
-
Immunotherapy advances for glioblastoma.Neuro Oncol. 2014 Nov;16(11):1441-58. doi: 10.1093/neuonc/nou212. Epub 2014 Sep 4. Neuro Oncol. 2014. PMID: 25190673 Free PMC article. Review.
-
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.Expert Rev Vaccines. 2013 Jun;12(6):597-615. doi: 10.1586/erv.13.41. Expert Rev Vaccines. 2013. PMID: 23750791 Free PMC article. Review.
-
Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro.PLoS One. 2019 Mar 6;14(3):e0212455. doi: 10.1371/journal.pone.0212455. eCollection 2019. PLoS One. 2019. PMID: 30840664 Free PMC article.
-
A dominant-negative mutant of the platelet-derived growth factor A-chain increases survival of hamsters implanted intracerebrally with the highly invasive CxT24-neo3 glioblastoma cell.J Neurooncol. 1998 Aug;39(1):33-46. doi: 10.1023/a:1005905217361. J Neurooncol. 1998. PMID: 9760068
-
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Front Oncol. 2016 Dec 7;6:256. doi: 10.3389/fonc.2016.00256. eCollection 2016. Front Oncol. 2016. PMID: 28003994 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical